IBD ratings are only valid with revenue producing companies. Insmed hopes to be delivering revenues in 2 years........Insmed currently carries a Zacks Rank #4 (Sell)...... All 5 brokerages who follow Insmed were paid from offerings by Insmed, inc. in the past 2 years..... The current valuation is not a paid analyst, a chart or a stupid posters guess.....it's $9.77. .... with the not so compelling Phase3 results and the dilution done, news of a different kind awaits. ....As far as a chart read, its very clear Good Luck
Gosh! how did the banks decide? ...and what the short interest report this eve WONT tell you.... July 1- Phase3 data of inferiority is released the stock closes @ $9.72 Hello!.
If the company plans a Phase3 in the US , the banks paid too much. If the company is allowed to file they probably paid about the right price, if the FDA finds problems in the data, the banks paid too much.
If NTM fails the banks paid WAAAAAY too much.The banks valued Insmed around 400 Million. There is risk going forward. YTD 117% in the bank , and my short blindsided by the dilution will be flat soon. Good Luck